Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Key Highlights
- ➤73% of patients achieved PSA reductions of at least 50%
- ➤47% achieved PSA reductions of at least 90%; four reached undetectable PSA
- ➤All seven patients with 90% PSA reductions remained progression-free beyond six months
- ➤No Grade 3 or higher treatment-related adverse events were reported
- ➤Pasritamig-JNJ-9401 combination is advancing to Phase 3 KLK2-comPAS
Expert Statements
Laura Graham, M.D., Assistant Professor of Medicine-Medical Oncology, University of Colorado School of Medicine
“Prostate cancer has long been difficult to treat with immunotherapy, which makes the activity we're seeing particularly interesting”
Laura Graham, M.D., Assistant Professor of Medicine-Medical Oncology, University of Colorado School of Medicine
“By combining two complementary approaches to T-cell activation, we are exploring a new way to engage the immune system against this disease.”
Laura Graham, M.D., Assistant Professor of Medicine-Medical Oncology, University of Colorado School of Medicine
“The depth of PSA reductions observed in this study, including responses sustained for six months or longer, provides encouraging early evidence for the pasritamig-JNJ-9401 combination that warrants further investigation in a larger Phase 3 study.”
Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson
“This novel dual-antigen-targeted bispecific regimen combines pasritamig, a foundational component of our prostate cancer pipeline, with JNJ-9401, highlighting the potential of complementary mechanisms working together”
Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson
“With this combination now in Phase 3 development, we are building on the early promise of this approach as we work to bring new treatment options to patients with advanced disease.”
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer PR Newswire
* First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer * Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11 of 15 patients) achieving reductions of at least 50% and nearly half achieving reductions of at least 90% in Phase 1 study * With an encouraging safety profile, findings show potential for outpatient dosing as the combination advances to Phase 3 NEW BRUNSWICK, N.J., Nov. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA), a marker used to monitor prostate cancer activity, including 47 percent (7 of 15 patients) who achieved reductions of at least 90 percent. Results were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4816973-1&h=1121996463&u=https%3A%2F%2Fwww.sitcancer.org%2F2026%2Fhome&a=Society+for+Immunotherapy+of+Cancer+(SITC)+2026+Annual+Meeting) (Abstract #1175).(1)
Get started
Create a free account to read the full story.